


Outcomes similar for therapy-related, de novo MDS after haplo-HSCT

February 21 2024, by Elana Gotkine



Patients with therapy-related myelodysplastic syndrome (t-MDS) and de novo MDS have comparable outcomes after haploidentical hematopoietic stem cell transplantation (haplo-HSCT), according to a study published online Feb. 8 in *Clinical and Experimental Medicine*.

Feifei Tang, from Peking University People's Hospital in Beijing, and colleagues conducted a retrospective analysis of 96 [patients](#) with MDS who received haplo-HSCT between January 2015 and December 2021 to compare clinical outcomes for t-MDS and de novo MDS. Using the case-pair method in a 1:8 ratio, 11 patients with t-MDS and 85 with de novo MDS were matched.

The researchers found that three-year overall survival and [disease-free survival](#) were not significantly different after haplo-HSCT for t-MDS versus de novo MDS (72.7 versus 75.1 percent and 54.5 versus 67.0 percent, respectively). The three-year cumulative incidence of relapse was 36.4 and 15.5 percent, respectively; no significant difference was seen in relapse in a multivariate analysis. The cumulative nonrelapse mortality rates at three years were 9.1 and 17.6 percent.

"Our study first demonstrated that t-MDS has comparable outcomes to de novo MDS after haplo-HSCT," the authors write. "Therefore, haplo-HSCT is one of the feasible options for t-MDS patients if there is no human leukocyte antigen-matched sibling."

More information: Feifei Tang et al, The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome, *Clinical and Experimental Medicine* (2024). [DOI: 10.1007/s10238-023-01287-8](https://doi.org/10.1007/s10238-023-01287-8)

Copyright © 2024 [HealthDay](#). All rights reserved.

Citation: Outcomes similar for therapy-related, de novo MDS after haplo-HSCT (2024, February 21) retrieved 29 April 2024 from <https://medicalxpress.com/news/2024-02-outcomes-similar-therapy-de-novo.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.